OLDSMAR, Fla. — July 7, 2017 — Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2017.
Consolidated revenues for the second quarter of fiscal 2017 were $6,200,000 compared to $5,800,000 for the second quarter of fiscal 2016. The revenues for the 2017 quarter consisted of $5,800,000 in processing and storage fee revenue, $329,000 in licensee and royalty income and $62,000 in product revenue compared to $5,300,000 in processing and storage fee revenue, $357,000 in licensee and royalty income and $66,000 in product revenue for the 2016 quarter
The Company reported net income for the three months ended May 31, 2017 of $497,000, or $0.07 per basic share and $0.06 per diluted share, compared to net income of 637,000, or $0.07 per basic and diluted share for the three months ended May 31, 2016. For the three months ended May 31, 2017, there was a 9% increase in processing and storage revenues, partially offset by an 11% increase in cost of sales and a less than 1% increase in selling, general and administrative expenses. Net income for the 2016 period resulted in part from a gain on extinguishment of debt in the amount of $300,593. The gain was a result of the Company’s payment in April 2016 of $778,000 representing payment in full to CytoMedical Design Group LLC (“CMDG”) pursuant to the terms of the original Asset Purchase Agreement and Promissory Note, as well as pursuant to the terms of the Loan/Promissory Note Sale Agreement and Mutual Release executed by the Company and CMDG on April 22, 2016.
Cash and Cash Equivalent Position
At May 31, 2017, the Company had cash and cash equivalents of $4,700,000. The Company’s cash increased $1,200,000 during the first six months of fiscal 2017. Cash provided by operations was $2,400,000 and cash provided by the sale of marketable securities was approximately $173,000 which were offset by $404,000 used for stock repurchases and $1,000,000 used to repay the note payable. On May 20, 2016, the Company entered into a Subordination Agreement with Texas Capital Bank and CrowdOut Capital LLC (“CrowdOut”) for a subordinated loan of the principal amount of $650,000, which amount CrowdOut advanced to the Company on May 20, 2016. In June 2017, the Company repaid the $650,000 principal amount of the subordinated loan.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com.
Statements wherein the terms “believes”, “intends”, “projects”, “anticipates”, “expects”, and similar expressions as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company’s global expansion initiatives and product diversification, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company’s menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.